DENALI Part 2 study of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC), study with parts 2a and 2b
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Azenosertib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DENALI Part 2
- Sponsors Zentalis Pharmaceuticals
- 04 Feb 2025 New trial record
- 29 Jan 2025 According to Zentalis Pharmaceuticals media release, the study is expected to begin 1H 2025. And, the topline data is anticipated by year end 2026.